INOVIQ Ltd
ASX:IIQ
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
INOVIQ Ltd
ASX:IIQ
|
46.5m AUD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
76.9B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
64.6B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
28.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24.2B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.2B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
23.1B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.8B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.2B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
INOVIQ Ltd
Glance View
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is focused on developing and commercializing a portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Company’s products include hTERT ICC test, which is an immunocytochemistry (ICC) assay that detects hTERT and is used as an adjunct to urine cytology, and EXO-NET RUO, which is a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. The company is also developing solutions using SubB2M, NETs, BARD1 and hTERT technologies to improve patient health outcomes.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for INOVIQ Ltd is -722.6%, which is above its 3-year median of -882%.
Over the last 3 years, INOVIQ Ltd’s Net Margin has increased from -5 314.3% to -722.6%. During this period, it reached a low of -5 314.3% on May 30, 2022 and a high of -722.6% on Jul 30, 2025.
